AngioDynamics (ANGO) Reports Q1 Loss, Tops Revenue Estimates
AngioDynamics (ANGO) delivered earnings and revenue surprises of +28.57% and +4.75%, respectively, for the quarter ended August 2025. Do the numbers hold clues to what lies ahead for the stock?